We investigated whether the resistin (Res) and adiponectin (Adp) levels are associated with different clinical blood pressure (BP) phenotypes. Among 465 consecutive never-treated white subjects, we excluded those with diabetes mellitus; impaired glucose metabolism; history of any cardiovascular disease or other concurrent medical condition; secondary hypertension; ongoing vasoactive treatment. Three separate clinic BP measurements and ambulatory BP monitoring were implemented to divide 328 subjects (aged 48±6 years; 172 males) into hypertensives (n ¼ 105), masked hypertensives (n ¼ 41), white-coat hypertensives (n ¼ 52) and normotensives (n ¼ 130). Participants underwent echocardiography and oral glucose tolerance testing, whereas, from fasting venous blood samples metabolic profile, plasma Res and Adp levels were assessed. Hypertensives and masked hypertensives showed higher log(10)(Res) and lower log(10)(Adp) levels compared with normotensives, whereas white-coat hypertensives had similar levels of these adipokines compared with normotensives. Common correlates for both of the adipokines were 24-h systolic BP, standing/sitting difference of both diastolic BP and heart rate, and waist circumference. Hypertensive and masked hypertensive compared with normotensive phenotype were independently associated with log(10)(Res) with odds ratios of 1.24 (1.08-1.44), and 1.16 (1.09-1.34) and log(10)(Adp) with 0.74 (0.65-0.87), and 0.81 (0.67-0.95), respectively. Increased Res and decreased Adp plasma levels are associated with out-of-clinic hypertension, whereas they did not determine whitecoat hypertension.
Introduction
Several potential mechanisms have been proposed to elucidate the overwhelming proportion of cardiovascular morbidity and mortality associated with increased adiposity. 1 In overweight and obese subjects, insulin resistance has a key role in the development of a complex of risk factors including hyperinsulinemia, hypertension, glucose intolerance and dyslipidaemia, which either in tandem or separately dramatically enhances cardiovascular risk. 2 Adipose tissue traditionally represents a depot for storing excess of energy in the form of triglycerides and resembles a secreting organ of hormones and molecular mediators with multi-systemic physiological actions including the vasculature. 3 Resistin (Res) and adiponectin (Adp) are two adiposesecreted signals with apparently opposite functions regarding the control of insulin sensitivity, 4, 5 regulation of endothelial function 6, 7 and systemic inflammatory load. 8, 9 Although there is a bidirectional association between endothelial dysfunction and sub-clinical inflammation with increased haemodynamic load, 10 it is yet unknown whether the actions of Res and Adp on the vasculature are translated into elevated BP; however, previous studies have shown that Res 11, 12 and Adp 13 are correlated with hypertension, but these studies have not been focused on ambulatory BP measurements.
As selective and combined elevation in clinic and ambulatory BP is associated with different cardiovascular risk with respect to normal BP, [14] [15] [16] [17] we aimed to investigate whether Res and Adp levels are associated with sustained, masked and white-coat hypertension. We hypothesized that there would be a difference in Res and Adp levels from subjects with normal BP, compared with those with whitecoat hypertension and masked hypertension and finally with those with sustained hypertension.
Materials and methods

Study design
A cross-sectional design was chosen to compare plasma Adp and Res among different clinical BP subgroups. A careful medical history was obtained, and all of the participants were also given clinical and echocardiographic examinations. Apart from a scheduled clinic BP evaluation, ambulatory BP monitoring and routine biochemical profile assessment complemented by oral glucose tolerance testing, we performed plasma Adp and Res measurements. The study protocol complies with the Declaration of Helsinki Principles and was approved by our institutional ethics committee. All of the participants gave written informed consent, and data were evaluated anonymously.
Setting and participants
We studied 465 consecutive never-treated with antihypertensive drugs white subjects, aged X30 years, who were self-referred to our outpatient hypertensive clinic for BP evaluation. Diagnosis of sustained hypertension was made in 190 subjects presenting a mean clinic systolic or diastolic BP4140 mm Hg and 490 mm Hg on three separate visits subsequently confirmed by 24-h ambulatory systolic or diastolic BP4130 mm Hg and 480 mm Hg. In addition, 67 subjects labelled as white-coat hypertensives showed mean systolic or diastolic clinic BP4140 and 490 mm Hg associated with 24-h ambulatory systolic and diastolic BPo130 mm Hg and o80 mm Hg. Masked hypertension (mean clinic systolic and diastolic BPo140 mm Hg and o90 mm Hg with 24-h ambulatory systolic or diastolic BP4130 mm Hg and 480 mm Hg) occurred in 51 subjects, whereas the remaining population was considered normotensive (n ¼ 157). 18, 19 We excluded subjects with diabetes mellitus (that is, treatment with anti-diabetic drugs or plasma glucose levels 46.94 mmol l À1 , impaired glucose tolerance (that is, fasting plasma glucose levels o7 mmol l À1 associated with an abnormal oral glucose tolerance test (2-h postload plasma glucose 7.7-11 mmol l À1 )), and high clinical evidence for familiar dyslipidaemia, as well as those with a history of any cardiovascular disease; secondary hypertension, including sleep apnea; and any other clinically significant concurrent medical condition (thyroidal, psychiatric, neuromuscular, kidney (estimated glomerular filtration rate o60 ml min À1 ), hepatic or gastrointestinal disease). Participants with a history or clinical/laboratory evidence of recent infection, inflammation or those who underwent any medical treatment (including lipidlowering, nonsteroidal anti-inflammatory and hormone replacement therapy) 1 month before entry in the study were also excluded.
Measurements
Clinic and ambulatory BP. BP measurement was made on three separate visits with a mean elapsing time of 1 week. In each visit, participants were encouraged to relax for B10 min, and subsequently, in a quiet room with a stable temperature and luminosity, an experienced cardiologist, after having explained the procedure to the participants, performed three different BP measurements at 5-min intervals by using a mercury sphygmomanometer. Korotkoff phases 1 and 5 were used to determine the systolic and diastolic BP, respectively; on each visit, the second and third BP measurements were averaged, and the final BP consisted of the mean of the three visits. Mean clinic heart rate was determined by averaging the three separate registered values of heart rate. Furthermore, a standing heart rate and BP measurement was performed on each visit after 2-min standing from the last sitting BP measurement. The mean standing heart rate and BP measurements were calculated by averaging the three values related to each visit. Finally, the mean difference between the standing and sitting BP and heart rate measurements was registered.
Over a working day (Monday through Friday) and just after the completion of clinic BP measurements of the third visit, ambulatory BP was recorded by using the automatic Spacelabs units 90207 (Redmond, WA, USA) by means of a procedure previously described in detail. 20 In brief, the cuff with the appropriate bladder size was fixed to the non-dominant arm, and the device was set to obtain the automatic heart rate and BP readings at 15-min intervals during the daytime and at 30-min intervals during the night time. Daytime and night time were defined using short fixed clock time intervals, which ranged from 1000 to 2000 hours and from 0000 to 0600 hours, respectively. Investigators performing ambulatory BP monitoring were blinded to the clinical status of the examinees. Twenty-fourhour systolic/diastolic BP and heart rate values were the mean of the overall 24-h recordings after artifact editing. More than 80% of successful readings were required to include a test as adequate for subsequent analysis. Subjects with night time BP fall X10% were defined as dippers and those with o10% as non-dippers.
Cardiac ultrasonography. The echocardiographic study was performed by an experienced senior operator who was blinded to the clinical status of the subject examined using a General Electric Medical System Vivid 3 PRO ultrasound imager equipped with a 2.5-5 MHz transducer (General Electric Medical System, Milwaukee, WI, USA), according to the guidelines of the American Society of Echocardiography. 21 Left ventricle mass was measured by using the formula of Devereux indexed for body surface area to estimate left ventricle mass index, whereas relative wall thickness was calculated using the appropriate formula. 22 Biochemical assessment. Venous blood samples were obtained from each participant after overnight fasting (from 0700 to 0900 hours) for the determination of the plasma glucose level, serum creatinine level and lipid profile (that is, total cholesterol, triglycerides and high lipoprotein cholesterol), according to established methods. Low-density lipoprotein cholesterol and estimated glomerular filtration rate were calculated by the Friedewald and Cockcroft-Gault formulas, respectively. An oral glucose tolerance test was performed in all of the participants according to the established procedure. Part of the blood specimens after centrifugation was stored at À80 1C until analysed; plasma total Adp (mg ml À1 ) and plasma Res (ng ml À1 ) were measured by enzyme-linked immunosorbent assay (RD195023100, Human Adiponectin ELISA Bio Vendor Laboratory Medicine, and RD191016100, Human Resistin ELISA Bio Vendor (Bio Vendor, Brno, Czech Republic), respectively). Samples were run in duplicate with average coefficient of variation between runs of 7.9% for Adp and 6% for Res.
Statistical analysis
The SPSS statistical package, release 15.0 (SPSS Inc, Chicago, IL, USA) was used for all of the statistical analyses. All of the descriptive continuous variables are presented as means and s.d. values if their distribution was normal (Shapiro-Wilk test), whereas the non-normally distributed variables are presented as medians and ranges. Owing to their skewed distribution, the Adp and Res values were logarithmically (log10) transformed before testing. Categorical variables are described with absolute and relative (percentages) frequencies.
Significant differences between the groups were determined using the analysis of variance pos hoc comparisons. To adjust for the inflation of type I error, owing to the high amount of multiple comparisons, we used the Bonferroni correction. As there were four groups, six pairwise comparisons were possible, and the differences were considered significant if the P-value was o0.008. Spearman's correlation coefficients were calculated to assess univariable associations between the examined adipokines with diverse cofactors. Simple bivariate correlation analysis was performed using the Pearson r correlation coefficient where appropriate.
Conditional linear multivariable regression analysis was used to examine the significant correlates of the logarithmically transformed Adp and Res. The candidate explanatory independent variables entered into the models were those that showed significant correlation in the univariate analysis, whereas age and sex were implemented by forced entry into the models. Metabolic syndrome was not entered in the analysis because it was highly interrelated with its components implemented as continuous variables into the models. To validate our linear multivariable models, we tested the normality and heteroscedasticity of the residuals produced. Any potential multicollinearity between the explanatory variables was tested by calculating the variance inflation factor and tolerance (1/variance inflation factor). No multicollinearity was found because tolerance values were 40.1. Thereafter, we performed a multinomial logistic stepwise (forward entry) regression analysis to test whether the logarithmically transformed Adp and Res were determinants of diverse clinical BP phenotypes by using as a reference the normotensive phenotype after adjustment for confounders. Determinants were also standardized for their standard deviation (z-scores) to compare the magnitude of their associations with the clinical BP phenotypes.
Results
Participants
From the initial study population, 137 subjects were excluded (that is, 17 because of diabetes mellitus; 30 because of impaired glucose tolerance; 7 because of high clinical evidence for familial dyslipidaemia; 39 because of cardiovascular diseases; 9 because of secondary hypertension; 11 for significant concurrent medical conditions; and 14 because of medical treatment), whereas 10 subjects although eligible for participation refused to give informed consent. After the implementation of the above during the recruitment period, those eligible to participate consisted of 328 subjects with diverse clinical BP phenotypes (that is, sustained hypertension, white-coat hypertension, masked hypertension and normal BP). Consequently, 105 hypertensives, 52 white-coat hypertensives, 41 masked hypertensives and 130 normotensives composed the final study population.
Main results: outcome data The rate of successful ambulatory BP readings was 92.5±4.5%. Table 1 presents the demographic and clinical characteristics of the study population, whereas Table 2 presents the biochemical and echocardiographic data. Although the groups showed similar demographic characteristics including body size, the different haemodynamic load registered by both clinic and ambulatory measurements was extended in the night time but without any difference regarding the dipping status. By contrast, significant differences were observed between the groups with respect to the difference between standing and sitting of both diastolic BP and heart rate. Between subgroups with diverse clinical BP phenotypes, kidney function, glycemic status, as well as left ventricle mass and geometry were similar, whereas total cholesterol, triglycerides and metabolic syndrome prevalence differed significantly.
Hypertensives compared with normotensive subjects presented higher log(10)(Res) levels, whereas log(10)(Adp) was decreased in the former group with respect to the latter (Po0.001, for both). In addition, hypertensives compared with masked hypertensives had similar levels of log(10)(Adp) and log(10)(Res) (P40.008 for both cases), whereas, compared with white-coat hypertensives, they presented higher levels of log(10)(Res) and lower levels of log(10)(Adp) (Po0.001, for both cases). White-coat hypertensives compared with masked hypertensives showed higher levels of log(10)(Adp) (Po0.001) and lower levels of log(10)(Res) (Po0.001, for both cases; Table 2) . Table 3 provides the Spearman univariable associations of log(10)(Adp) and log(10)(Res) with a variety of cofactors. Interestingly, the associations of log(10)(Adp) with the studied cofactors were of the inverse direction with respect to those of log(10) (Res). Pearson's r coefficient for the interrelationships between log(10)(Adp) with log(10)(Res) was À0.58, Po0.001 in the total study population.
We analysed two different conditional linear multivariable regression models (Table 4 ) using as dependent variables log(10)(Adp) (overall model fit: R 2 adjusted ¼ 62%, Po0.001) and log(10)(Res) (overall model fit: R 2 adjusted ¼ 53.8%, Po0.001), respectively. Common significant correlates for both of the logarithmically transformed adipokines were 24-h systolic BP, standing/sitting difference of both diastolic BP and heart rate and waist circumference, whereas additional significant correlate for log(10)(Adp) was plasma glucose and for log(10)(Res) they were left ventricle mass index and estimated glomerular filtration rate.
Finally, by using multinomial logistic multivariable models, both sustained hypertension and masked hypertension were independently associated with the studied adipokines after adjustment for cofactors, in contrast with the white-coat hypertensive phenotype (Table 5) . In Figure 1 , we present the magnitude of the above associations by means of z-scores; hypertensive phenotype was more strongly associated with log(10)(Res) compared with log(10) (Adp), whereas for masked hypertensive phenotype the inverse phenomenon was detected.
Discussion
The salient finding of this study is that increased Res and decreased Adp plasma levels were associated with sustained and masked hypertension, whereas they did not determine the white-coat hypertensive phenotype. A secondary finding is that Res was associated B2.5 times more frequently with sustained hypertension than with masked hypertension, whereas Adp determined the latter phenotypes to the same extent. These findings suggest that inappropriate levels of circulating adipose tissue-secreted signals, namely hyperresistinemia and hypoadiponectinemia, may accompany the out-of-clinic hypertensive BP phenotypes identified either as sustained or masked hypertension, possibly resembling an obscured haemodynamic pressor lever. This is the first study to systematically examine the association of different BP clinical phenotypes with adipokines having an opposite physiological effect on cardiometabolic risk factors; we have previously used a similar design to test the association of free leptin with clinical BP phenotypes. 23 In addition, we have shown that higher levels of Res and lower levels of Adp are observed among prehypertensive and masked hypertensive subjects with respect to their normotensive counterparts matched for age, sex and body mass index. 24, 25 The healthy offspring of hypertensive subjects are characterized by hyperresistinemia and hypoadiponectinemia, suggesting that the latter 'circulating duo' may precede and contribute to the development of hypertension, rather than being secondary to the increased BP. 26 Our previous findings are confirmed in the larger group of subjects characterized by non-impaired glucose metabolism and after the exclusion of those with comorbidities or ongoing vasoactive therapy.
Although the pathophysiological role of Res on the vasculature remains unclear, accumulating evidence supports that it promotes endothelial dysfunction and proinflammatory activation, lead- Abbreviations: Adp, adiponectin; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HDL, highdensity lipoprotein; HR, heart rate; LDL, low-density lipoprotein; LVMI, left ventricle mass index; Res, resistin; RWT, relative wall thickness.
Adipokines and clinical BP phenotypes C Thomopoulos et al ing to acceleration of sub-clinical atherosclerosis, 27 whereas there is in vitro evidence that promotes endothelial cell activation with increased endothelin-1 transcription and increased expression of the adhesion molecule VCAM-1, and enhances tumour necrosis factor-a expression. 6 Furthermore, there is evidence that Adp inhibits the induction of the adhesion molecule VCAM-1 and intercellular adhesion molecule-1 in endothelial cells by Res, suggesting that the balance of the opposing effects of these adipokines at the level of the endothelial cell might be an important determinant of endothelial Table 4 Correlates of log(10)(Adp) and log(10)(Res) A reference category for the dependent variable was considered the normotensive BP phenotype; Adp, adiponectin; Res, resistin; cofactors entered in all models were age, sex, smoking status, waist circumference, 24-h heart rate, difference standing minus sitting diastolic BP, difference standing minus sitting heart rate, low-density lipoprotein cholesterol, plasma glucose, estimated glomerular filtration rate and left ventricle mass index.
Adipokines and clinical BP phenotypes C Thomopoulos et al dysfunction. 28 Although in vivo studies for the effects of Res on the vasculature are rather scarce, 29 the lack of Adp in knockout mice heightens the neointimal thickening and proliferation of vascular smooth muscle cells in mechanically injured arteries, 30 whereas display impaired endotheliumdependent vasodilation and nitric oxide production. 31, 32 Finally, there is growing evidence that Adp antagonizes renin-angiotensin system activation 33, 34 and that the centrally-mediated sympathetic nervous system activation may be at least partially modulated by a 'hidden interplay' between leptin and Adp. 35, 36 Taking together the above, the association between BP levels and circulating adipokines may share a reciprocal modulation with sympathetic activation, systemic inflammation and endothelial dysfunction, anticipating adverse BP clinical phenotypes such as sustained and masked hypertension with possible adverse repercussion on cardiovascular and metabolic outcomes. [37] [38] [39] [40] In the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study, the independent contributor to worsening of hypertension status, apart from the baseline BP and age, was plasma glucose, and subjects with masked hypertension were at increased risk for developing sustained hypertension. 41 On the basis of the results of the PAMELA study, our findings further suggest that Res and Adp may have a role in the relentless progression from normal BP toward out-of-clinic hypertensive states, because they were correlated with 24-h BP levels, haemodynamic postural reactions to standing (clinical measure of sympathetic overdrive), metabolic parameters and waist circumference as components of the metabolic syndrome and finally left ventricle mass. The missing association of white-coat hypertension with inappropriate levels of the studied adipokines, even after adjustment for confounders including postural reactions to standing, suggests that these molecular signals might not be implicated on the association of isolated clinic hypertension with target organ damage. 42 Further clinical studies are needed to confirm the possible prognostic value of Res and Adp on BP levels, including the determination of the physiologically relevant concentrations of the measures associated with adverse clinical BP phenotypes. On the presumption that both of the measures are associated with the out-of-clinic clinical BP phenotypes, and that drugs blocking the renin-angiotensin system proved to increase Adp levels, it should be tested whether these drugs are equally effective for reducing Res levels. Finally, Res and Adp could be considered candidate markers for cardio-metabolic risk determination and possibly novel therapeutic targets for hypertension.
The cross-sectional nature of the study limits the ability to infer any causal or temporal relationship between the studied adipokines with clinical BP phenotypes. Furthermore, given that our sample consisted of subjects of European descent, prevalently middle-aged who were referred to our hypertension clinic, the results could not be directly extendable to other ethnicities, different ages or the general population. Although we excluded the peripheral component of insulin resistance, the central one related to fasting insulin levels could not be ruled out definitely and the exclusion of those with impaired fasting glucose and glucose Figure 1 Comparative per magnitude associations (z-scores) of the logarithmically transformed Adp and Res with diverse clinical BP phenotypes after adjustment for confounders (age, sex, smoking status, waist circumference, 24-h heart rate, difference standing minus sitting diastolic BP, difference standing minus sitting heart rate, low-density lipoprotein cholesterol, plasma glucose, estimated glomerular filtration rate and left ventricle mass index) entered in the multinomial regression models. Reference category (adjusted z-score ¼ 0) was considered the normotensive phenotype; Adp, adiponectin; Res, resistin; numbers within the table indicate z-scores. *Po0.008 for the comparisons with the reference phenotype;
tolerance test makes the findings relevant only in normoglycemic subjects. Finally, we did not perform measurements of systemic inflammation surrogate (for example, high sensitivity C-reactive protein), which may have affected our results.
In conclusion, white-coat hypertensive and normotensive phenotypes are associated with more the favourable circulating adipokine pattern, whereas masked and sustained hypertension are associated with decreased Adp and increased Res in middleaged normoglycemic subjects.
